We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A House committee is asking for a review of the FDA’s progress in ensuring the security of foreign facilities’ supply chains and toughening the agency’s approach to inspections at those facilities. Read More
Illegal conduct in the compounding and dietary supplement industries are two of the U.S. Department of Justice’s top three areas of increased focus, a deputy assistant attorney general said Dec. 9, 2015. Read More
Lawmakers are threatening the pharmaceutical industry’s reigning bad boy Martin Shkreli with a contempt citation if he fails to show up for next week’s hearing on drug prices. Read More
The FDA has updated its list of scheduled guidances for the calendar year 2016, with a major focus on pharmaceutical quality, data integrity and generics. There are 102 planned guidances this year, compared with 92 last year. Read More
The FDA repeatedly blasted overseas drugmakers last year for disregarding previous inspection findings and not living up to promises to carry out proper GMP practices for active pharmaceutical ingredients. Read More
With congressional efforts to pressure Gilead Sciences into lowering the price of two hepatitis C drugs floundering, members of the Senate Finance Committee are taking their concerns directly to the public. Read More